



Erratum

Erratum to “INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease” [J Prev Alzheimers Dis 2025;12(1): 100005.]

Eric Siemers^{a,*}, Todd Feaster^a, Gopalan Sethuraman^a, Karen Sundell^a, Vladimir Skljarevski^a, Erika N. Cline^a, Hao Zhang^a, Jasna Jerecic^a, Lawrence S. Honig^b, Stephen Salloway^c, Reisa Sperling^d, Mirjam N. Trame^e, Michael G. Dodds^e, Kimball Johnson^f

^a Acumen Pharmaceuticals, Newton, MA, USA

^b Columbia University Irving Medical Center, New York, NY, USA

^c Butler Hospital and Brown University, Providence, RI, USA

^d Harvard Medical School, Boston, MA, USA

^e Certara USA, Inc., Princeton NJ, USA

^f CenExel iResearch, Atlanta, GA, USA

We regret that the Declaration of competing interest section in this article was followed by the statement "none," despite the authors having provided their full declaration. This omission occurred during the production process by the publisher.

The authors' declaration of competing interest is as follows:

Declaration of competing interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Eric Siemers, Todd Feaster, Gopalan Sethuraman, Karen Sundell, Erika N. Cline, Hao Zhang, and Jasna Jerecic are employees of, and minor stockholders in Acumen Pharmaceuticals, Inc.

Vladimir Skljarevski is a paid consultant of Acumen Pharmaceuticals, Inc.

Lawrence S. Honig received grants of research funding from Acumen Pharmaceuticals, Inc., AbbVie, Alector, Biogen, Bristol-Myers Squibb, Cognition, EIP, Eisai, Ferrer, GemVax, Genentech/Roche, GSK, Janssen/J&J, Transposon, UCB, Vaccinex, and consultant fees from Biogen, Corium, Eisai, Genentech/Roche, New Amsterdam, Prevail/Lilly.

Stephen Salloway received grants of research funding from Acumen Pharmaceuticals, Inc., research support paid to Butler Hospital from Janssen, Eli Lilly and Company, Eisai, Genentech, Roche, Biogen and consulting fees from Eisai, Biogen, Eli Lilly and Company, Roche, Genentech, Bolden, Novo Nordisk, Prothena, Acumen Pharmaceuticals, Labcorp, Alector, Corium, Kisbee, Biohaven, AbbVie.

Reisa Sperling has served as a consultant for AbbVie, AC Immune, Acumen Pharmaceuticals, Inc., Alector, Alnylam, Biohaven, Bristol Myers Squibb, Genentech, Janssen, JOMDD, Nervgen, Neuraly, Neurocentria, Oligomerix, Prothena, Renew, Roche, Shionogi, Vigil Neuroscience, Ionis, and Vaxxinity. She has received travel support from the Alzheimer's Association and Clinical Trials in Alzheimer's Disease. Her institution has received grants or research funding from Alzheimer's Association, National Institute on Aging, GHR Foundation, Eisai, Eli Lilly and Company, and National Institutes of Health.

Mirjam N. Trame and Michael G. Dodds are employees of Certara, which was under contract with Acumen Pharmaceuticals, Inc. during the time of the study.

As PI in the trial, Kimball Johnson's institution received payments from Acumen Pharmaceuticals, Inc.

The Publisher would like to apologize for any inconvenience caused.

DOI of original article: [10.1016/j.tjpad.2024.100005](https://doi.org/10.1016/j.tjpad.2024.100005)

* Corresponding author at: 1210-1220 Washington St., Suite 210 Newton, MA 02465.

E-mail address: esiemers@acumenpharm.com (E. Siemers).

<https://doi.org/10.1016/j.tjpad.2025.100213>